Search results
Results from the WOW.Com Content Network
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
There is no cure for Lupus. The treatment of SLE involves preventing flares and reducing their severity and duration when they occur. [118] Treatment can include corticosteroids and anti-malarial drugs. Certain types of lupus nephritis such as diffuse proliferative glomerulonephritis require intermittent cytotoxic drugs.
The Lupus Research Alliance (LRA) is an American voluntary health organization based in New York City whose mission is to find better treatments and ultimately prevent and cure systemic lupus erythematosus (SLE or lupus), a debilitating autoimmune disease, through supporting medical research. The organization was born from the merger of three ...
For premium support please call: 800-290-4726 more ways to reach us
The project publishes drug reports. The first three reports covered Statins to reduce high cholesterol, heartburn drugs, and NSAIDs commonly used to treat arthritis. The project covers over 20 conditions and the most widely used drugs. [5] The reports are published in web versions and two-page PDF summaries in English and Spanish.
Lupus has historically been difficult to treat. Many of the current options broadly suppress the immune system, including beneficial T cells that fight infection. And for some people with the ...
When treatment with DMARDs fails, cyclophosphamide or steroid pulse therapy is often used to stabilise uncontrolled autoimmune disease. Some severe autoimmune diseases are being treated with bone marrow transplants in clinical trials , usually after cyclophosphamide therapy has failed.
In 1999, Johnson & Johnson had signed a contract with a company called Excerpta Medica. Its specialty was medical marketing. Its sub-specialty was producing ghostwritten, data-filled studies on the efficacy and safety of a client’s drugs, finding the right academic scholars to be listed as the authors and then placing the articles in prestigious academic journals.